Table 3

Guidelines for follow-up in ovarian cancer

Ovarian cancerClinic-based follow-upTelephone follow-up ± blood testPIFU
Low risk (<10% ROR, stage 1A/B fully staged) from end of treatment (surgery ± chemotherapy). Excluding fertility sparing surgeryCan be offered if declines PIFU for 2 years from end of treatmentCan be offered if declines PIFU for 2 years from end of treatmentOffer from end of treatment (after holistic needs assessment at 3 months)
FIGO stages 1C–4For 3 years from end of treatmentCan be offered for years 4-5 from end of treatmentNot suitable
  • PIFU, patient-initiated follow-up; ROR, risk of recurrence.